These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 16969289

  • 1. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
    Hazzan M, Buob D, Labalette M, Provot F, Glowacki F, Hoffmann M, Copin MC, Noel C.
    Transplantation; 2006 Sep 15; 82(5):657-62. PubMed ID: 16969289
    [Abstract] [Full Text] [Related]

  • 2. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 5. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A.
    Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603
    [Abstract] [Full Text] [Related]

  • 6. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 7. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE, El-Dahshan K, Mahmoud K, Ismail AM, El-Baz M, Shokeir AA, Ghoneim MA.
    Exp Clin Transplant; 2008 Sep 27; 6(3):203-10. PubMed ID: 18954298
    [Abstract] [Full Text] [Related]

  • 8. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N, Rodger RS, McMillan MA, Junor BJ.
    Transplantation; 2007 Mar 15; 83(5):582-7. PubMed ID: 17353778
    [Abstract] [Full Text] [Related]

  • 9. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 15; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 10. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 15; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine A withdrawal during follow-up after pediatric liver transplantation.
    Scheenstra R, Torringa ML, Waalkens HJ, Middelveld EH, Peeters PM, Slooff MJ, Gouw AS, Verkade HJ, Bijleveld CM.
    Liver Transpl; 2006 Feb 15; 12(2):240-6. PubMed ID: 16447209
    [Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C.
    J Am Soc Nephrol; 2005 Aug 27; 16(8):2509-16. PubMed ID: 15987748
    [Abstract] [Full Text] [Related]

  • 14. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A, Biedunkiewicz B, Król E, Debska-Slizień A, Rutkowski B.
    Transplant Proc; 2006 Aug 27; 38(1):81-5. PubMed ID: 16504670
    [Abstract] [Full Text] [Related]

  • 15. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V, Fritsche L, Haller H, Suwelack B, Abendroth D, Fornara P, Pietruck F, Frei U, Donauer J, Lison AE, Michel U, Ulbricht B, International MOST Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1597-600. PubMed ID: 15866683
    [Abstract] [Full Text] [Related]

  • 16. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO, Dias MF, Pacheco-Silva A.
    Clin Transplant; 2004 Aug 27; 18(4):450-5. PubMed ID: 15233825
    [Abstract] [Full Text] [Related]

  • 17. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X, Johnston A.
    Transplant Proc; 2004 Jun 27; 36(5):1321-6. PubMed ID: 15251323
    [Abstract] [Full Text] [Related]

  • 18. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P.
    Transpl Int; 2002 Nov 27; 15(11):550-5. PubMed ID: 12461659
    [Abstract] [Full Text] [Related]

  • 19. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
    Satoskar AA, Lehman AM, Nadasdy GM, Sedmak DD, Pesavento TE, Henry ML, Pelletier RP, Ferguson RM, Nadasdy T.
    Clin Transplant; 2008 Nov 27; 22(1):61-7. PubMed ID: 18217907
    [Abstract] [Full Text] [Related]

  • 20. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction].
    Mota A.
    Acta Med Port; 2004 Nov 27; 17(1):8-14. PubMed ID: 15636737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.